Work

Phase 1 study of TT-00973-MS, a highly selective and potent AXL inhibitor, in patients with advanced solid tumors.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.3106

Authors: Bo Yang, Huan Zhou, Haiyan Yang, Zhengzheng Chen, Caixia Sun, Shumao Ni, Peng Peng, Zejuan Sheng, Xu Du, Jia Wang, Ping Wang, Hongchan Zhang, Min Liao, Zhenjiu Gou, Fulan Wei, Jean Fan, Jing Wang

Institutions: First Affiliated Hospital of Bengbu Medical College, Central South University, Hunan Cancer Hospital, University of Science and Technology of China

Language: English

Topic: Cancer Mechanisms and Therapy

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410822804

Cites:

Cited by:

Related to: 10